贝达药业(300558.SZ)：拟投资杭州知兴制药有限公司

Core Viewpoint - Beida Pharmaceutical has completed a share transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, focusing on high-barrier technology in the biopharmaceutical sector [1] Group 1: Company Strategy - The company aims to leverage its advantages in the biopharmaceutical field by enhancing its ecosystem around high-barrier technology [1] - The investment of 50 million RMB in Zhixing Pharmaceutical is part of the company's strategy to strengthen its position in the market [1] Group 2: Zhixing Pharmaceutical Overview - Zhixing Pharmaceutical specializes in the development of high-end inhalation formulations and has established a robust R&D and production system [1] - The company has successfully built a leading domestic research platform for aerosol formulations, overcoming key technical challenges such as particle size control and process stability [1] Group 3: Product Pipeline - Zhixing Pharmaceutical has three products in its pipeline targeting asthma and COPD, all of which have completed bioequivalence (BE) testing [1] - The product "Fluticasone Propionate Nebulized Suspension" is nearing market application, indicating a strong potential for commercialization [1] - The company plans to focus on high-barrier products monopolized by multinational pharmaceutical companies while also developing improved and innovative drugs [1]